X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/03/27/2853169/0/en/NEW-SCIENTIFIC-PUBLICATION-SHOWS-LB-100-LIXTE-S-LEAD-CLINICAL-COMPOUND-CAN-FORCE-CANCER-CELLS-TO-GIVE-UP-THEIR-CANCER-CAUSING-PROPERTIES.html
https://www.globenewswire.com/news-release/2024/03/21/2850210/0/en/LIXTE-Provides-Update-on-Progress-with-LB-100-as-a-PP2A-Inhibitor-to-Enhance-Chemotherapy-and-Immunotherapy-Cancer-Treatments.html
https://www.globenewswire.com/news-release/2024/01/29/2818900/0/en/First-Patient-Dosed-with-LIXTE-s-LB-100-and-GSK-s-Immunotherapy-Dostarlimab-gxly-in-Ovarian-Clear-Cell-Carcinoma-Trial.html
https://www.globenewswire.com//news-release/2023/11/13/2779074/0/en/LIXTE-Biotechnology-Provides-Update-on-Clinical-Progress-and-Expanding-Collaborations.html
https://www.globenewswire.com//news-release/2023/10/16/2760671/0/en/LIXTE-Netherlands-Cancer-Institute-and-Oncode-Institute-to-Expand-Collaboration.html
https://www.globenewswire.com//news-release/2023/10/09/2756673/0/en/LIXTE-Biotechnology-Holdings-Announces-the-Passing-of-its-Founder-John-S-Kovach.html
https://www.globenewswire.com//news-release/2023/09/26/2749505/0/en/LIXTE-Appoints-Bas-van-der-Baan-as-President-and-Chief-Executive-Officer.html
https://www.globenewswire.com//news-release/2023/09/20/2746468/0/en/LIXTE-Biotechnology-Announces-a-Supported-Collaborative-Trial-to-Study-LIXTE-s-First-in-Class-PP2A-Inhibitor-LB-100-Plus-GSK-s-Immunotherapy-Dostarlimab-in-Clear-Cell-Ovarian-Cance.html
https://www.globenewswire.com/news-release/2023/07/20/2708565/0/en/LIXTE-Biotechnology-Announces-Closing-of-3-5-Million-Registered-Direct-Offering-and-Concurrent-Private-Placement-Priced-At-the-Market-under-Nasdaq-Rules.html
https://www.globenewswire.com/news-release/2023/07/18/2706358/0/en/LIXTE-Biotechnology-Announces-Pricing-of-3-5-Million-Registered-Direct-Offering-and-Concurrent-Private-Placement-Priced-At-the-Market-under-Nasdaq-Rules.html
Market Place
Share 
